We investigated the predictors of time from metastatic castration-resistant prostate cancer (mCRPC) to allcause mortality among patients treated at Veteran Affairs hospitals. We found that age, more remote year of mCRPC, greater number of bone metastasis, higher prostate-specific antigen levels, and shorter prostatespecific antigen doubling time at mCRPC diagnosis were associated with shorter overall survival. A nomogram was generated yielding good concordance and calibration. Objective: To identify the predictors of time from initial diagnosis of metastatic castration-resistance prostate cancer (mCRPC) to all-cause death within the Shared Equal Access Regional Cancer Hospital cohort. Patients and Methods:
Introduction
Although metastatic castration-resistant prostate cancer (mCRPC) patients generally have an unfavorable prognosis, not all patients have an identical clinical course. Indeed, some patients quickly experience progression to widespread metastatic disease and die of cancer, while others have a much more indolent disease progression. 1 Previously, several predictive models have been proposed to estimate the survival of mCRPC patients. [2] [3] [4] [5] However, most of these studies used data from clinical trials evaluating patients after chemotherapy. Given the availability of new nonchemotherapic agents to treat mCRPC in recent years, including sipuleucel T, 6 abiraterone, 7 enzalutamide, 8 and radium-223, 9 not all patients receive chemotherapy immediately after mCRPC diagnosis. The survival and predictors of mortality at the time of initial mCRPC diagnosis, before any treatment is received, have been evaluated in a few studies. 10 Moreover, given that patients in clinical trials are generally a highly selected group that does not necessarily represent the average mCRPC population (ie, healthy enough to undergo an experimental therapy) along with well-known low rates of trial participation among black men and men of lower socioeconomic status, survival studies using clinical databases that are more likely to reflect survival probabilities outside clinical trials are needed. 11 We thus investigated the predictors of time from mCRPC diagnosis to all-cause mortality among patients within the Shared Equal Access Regional Cancer Hospital (SEARCH), a database of patients with prostate cancer (PC) treated at Veteran Affairs hospitals. We developed a nomogram to predict the survival probabilities at 1, 2, 3, and 5 years after mCRPC diagnosis.
Methods

Study Population
After obtaining institutional review board approval, data from PC patients who received androgen deprivation therapy (ADT) between 1983 and 2013 at 2 Veteran Affairs medical centers (San Diego, CA, and Durham, NC) and had prostate-specific antigen (PSA) levels ! 2 ng/mL after initiating ADT were abstracted into an electronic database. The database included information on patient age at time of mCRPC, race, PSA levels and kinetics (such as PSA doubling time [PSADT] and PSA velocity [PSAV]), tumor pathology (Gleason grade and stage), radiology studies (including simple x-rays, bone scans, computed tomography scans, and magnetic resonance imaging), primary and secondary treatments for PC, and overall survival. 12 A total of 7888 subjects receiving ADT for PC with PSA levels ! 2 ng/mL after initiating ADT were entered in the database. Of these, 459 (9%) had documented CRPC as defined by PSA progression per PC Working Group 2 definition (relative increase of 25% and absolute increase of 2 ng/mL or more above nadir) in patients receiving continuous ADT (gonadotropinreleasing hormone agonist, antagonist, or bilateral orchiectomy), with no evidence of metastatic disease before CRPC diagnosis (ie, M0CRPC), and were diagnosed with CRPC in 2000 or later. 13 The rationale to exclude men with metastasis before CRPC was to generate a cohort of men who all had initial an diagnosis of mCRPC without having had previous metastases. We limited our analysis to men diagnosed with CRPC in the year 2000 or later, as electronic databases within the Veteran Affairs Health System were limited before 2000. The characteristics of these 459 men have been described previously. 14 Of these 459 men with nonmetastatic CRPC, 202 (28%) did not develop metastatic disease during followup and were excluded. Of the remaining 257 patients who had developed documented mCRPC, 52 (20%) had missing PSA or treatment data and were excluded. This resulted in a final study sample of 205 patients (80%) (Figure 1 ). Primary and secondary treatments for PC were at the discretion of the patient and treating physician.
Statistical Analysis
Baseline patient and disease characteristics at the time of mCRPC diagnosis are presented as absolute numbers and percentages, and as median and interquartile range (IQR) for categorical and continuous variables, respectively (Table 1) . Time from mCRPC diagnosis 15 For nomogram development, variable selection was conducted using the Akaike information criterion stepwise algorithm. 16 Multicollinearity was evaluated using variation inflation factor. The nomogram was created on the basis of the Cox proportional hazards regression model and designed to predict overall survival probabilities at 1, 2, 3, and 5 years after mCRPC diagnosis. We internally validated the nomogram by determining the overall unadjusted and biascorrected concordance index using bootstrapping (200 repetitions) and generating a calibration plot comparing predicted and actuarial overall survivals 2 years after mCRPC diagnosis. All statistical analyses were performed by Stata 12.1 (StataCorp, College Station, TX) and R 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). A 2-sided P < .05 was considered to indicate statistical significance.
Results
The were black. Biopsy Gleason score was 2-6 in 31 cases (15%), 3 þ 4 in 37 (18%), 4 þ 3-10 in 65 (32%), and unknown/not available in 72 (35%). Local treatment for PC was none in 85 cases (41%), radical prostatectomy AE radiation AE ADT in 49 (24%), and radiation AE ADT in 71 (35%). A total of 181 patients (88%) had at least one bone metastasis, 145 (71%) at least 2 bone metastases, and 53 (26%) had 10 or more bone metastases, while 24 (12%) had visceral/lymph node metastasis only. Metastasis to lymph nodes was present in 40 patients (20%), while visceral metastasis was observed in 15 patients (7%). Of these, metastasis to the liver, lung, and other organs was found in 7, 1, and 8 patients, respectively. 
Predicting Time From Metastasis to Overall Survival
A total of 170 patients (83%) died over a median follow-up of 41 (IQR, 27-80) months. The median survival was 13 months (Figure 2) . In univariable analysis, older age at mCRPC, more remote year of mCRPC diagnosis, nonblack race, greater number of bone metastasis, higher PSA levels, shorter PSADT, and faster PSAV at mCRPC were significantly associated with shorter time from mCRPC diagnosis to all-cause death. In multivariable analysis, older age at mCRPC, more remote year of mCRPC diagnosis, greater number of bone metastasis, higher PSA levels, and shorter PSADT at mCRPC remained significantly associated with shorter time from mCRPC diagnosis to all-cause death ( Table 2) .
On the basis of the multivariable model, a nomogram predicting overall survival probabilities at 1, 2, 3, and 5 years after mCRPC diagnosis was generated ( Discussion mCRPC is considered a late stage in the natural history of PC. Although mCRPC is usually associated with an ominous prognosis, many patients experience a more indolent disease progression. Indeed, although we found the median survival of mCRPC patients in our series with a median year of mCRPC diagnosis of 2007 to be only 13 months, our data suggest approximately 15% survived beyond 5 years. Given this heterogeneity in prognosis, we sought to identify the predictors of time from metastasis to mortality among mCRPC patients within the SEARCH cohort. We found older age at mCRPC, more remote year of mCRPC diagnosis, greater number of bone metastases, higher PSA levels, and shorter PSADT at mCRPC were independently associated with shorter time from 17 to 32 months in more recent trials of men receiving enzalutamide. 8 In the current study, median survival was 13 months, which is lower than prior studies. This is likely due to several factors. First, median year of diagnosis in our study was 2007. Thus, the majority of men were diagnosed and treated in the docetaxel-only era (ie, before the availability of recent agents that have been shown to extend survival). As such, our median 13-month survival is not far from the TAX 327 study (randomized trial of mitoxantrone vs. docetaxel) wherein median survival was 16.5 months for mitoxantrone and 18.9 for docetaxel. Second, consistent with this, year of mCRPC diagnosis was one of the strongest risk factors for survival. Indeed, the effect for each 1 year of more recent diagnosis (adjusting for baseline characteristics) was a 7% death risk reduction. This effect, compounded over 8 years (from median year of diagnosis of 2007 to 2015), would result in a hazard ratio for death of 0.56 in the year 2015 compared to 2007 (median in the current study) and translate into a median 23-month survival for men diagnosed in 2015. Third, our study was not limited to clinical trial patients but represents data from clinical practice outside a clinical trial environment. It has been shown that patients enrolled onto clinical trials outperform nontrial patients even if randomized to standard of care. 18 As such, survival estimates based on clinical trial data may overestimate survival and give false hope to patients. Fourth, consistent with this, the age of patients in our study was older than in clinical trials of mCRPC patients. Our sample's median age was 74 years compared to 68 in TAX 327, 17, 19 71 in Cougar 302 (prechemotherapy trial of abiraterone þ prednisone vs. prednisone), 20 and 72 in PREVAIL (prechemotherapy trial of enzalutamide vs. placebo). 8 For each 1 year older, the risk of death was 4% higher in our study. Thus, adjusting a 74-year-old median age down to 72, as in PREVAIL, would improve our median survival by 8% to 25 months, which is only slightly worse than the 30-month survival for placebo-treated patients. Thus, while 13-month median survival for our whole cohort is quite low for Predicting Time From Metastasis to Overall Survival modern mCRPC, accounting for year of mCRPC diagnosis and age at mCRPC diagnosis, our data would predict a survival that is in line with, albeit somewhat lower than, the most recent clinical trial data. As such, we believe our findings are robust and present data for nontrial patients. Obviously, other observational data sets will be required to validate our findings. While median survival for a man diagnosed with mCRPC today may be 2 to 3 years, there is tremendous heterogeneity of prognosis among mCRPC patients. As such, several studies evaluated the predictors of mortality in mCRPC. For example, Halabi et al 2 found
worse performance status, visceral metastasis, higher lactate dehydrogenase, more opioid analgesic use, lower serum albumin, lower hemoglobin, higher PSA levels, and higher alkaline phosphatase to be associated with worse overall survival. Similarly, Pond et al, 21 evaluating 1006 men treated with docetaxel in a clinical trial, found men with lymph nodeeonly metastatic disease had the most favorable prognosis among mCRPC patients. However, those with liver metastases had the worst overall survival. Likewise, Armstrong et al 4 showed the presence of liver metastases, greater number of metastatic sites, clinically significant pain, worse performance status, shorter PSADT, higher PSA levels, higher tumor grade, higher alkaline phosphatase, and lower hemoglobin to be independent factors associated with increased mortality. Similar to these previous findings, in our study, we found that older age at mCRPC, more remote year of mCRPC diagnosis, greater number of bone metastasis, higher PSA levels, and shorter PSADT at mCRPC were independently associated with shorter overall survival. Thus, given that the factors associated with prognosis in our study were similar to the ones reported before, our findings using a clinical data set validate the variable selection used in previous predictive models that used data from clinical trials. However, as discussed above, the models from clinical trials, given they may overestimate survival, need to be validated in clinical data sets. The same applies to our model. Although our nomogram had an acceptable concordance and good calibration, external validation of our findings are still required to evaluate its performance in a sample other than the development cohort.
Although our overall number of patients was small, we had a sizable percentage of black men. We found that black men had similar (multivariable) or better (univariable) outcomes compared to nonblack men. This is important in that black men generally have more aggressive PC. However, our findings are in line with a prior study from the Cancer and Leukemia Group B, which showed across multiple trials that black men had similar, if not better, outcomes. 22 The reasons for this are not clear. Whether this reflects improved responsiveness to second-and third-line treatments is unknown. Unfortunately, as most clinical trials include a dearth of black men, answering this question using clinical trial data will be virtually impossible. The present study is limited by the retrospective nature of our cohort. As such, we had no control over how patients were treated before or after the diagnosis of mCRPC. Consequently, it is likely that with the development of newer agents to treat mCRPC in recent years (such as abiraterone and enzalutamide), the prognosis of mCRPC patients has changed over time. Although we adjusted our multivariable model for year of mCRPC diagnosis, we were unable to adjust for mCRPC treatment received, as the data were not available for all patients. Moreover, it is likely that the prognosis of mCRPC patients will continue to improve, which may cause the current nomogram to overestimate the risk of death. Furthermore, important variables that have been previously correlated with survival, such as performance status, comorbidities, and various laboratory tests, were not available and thus were not included in our models. Based on this, we were unable to validate these external models or compare performance of our model to theirs. Missing data was an issue, given we had to exclude 20% of our initial sample due to missing data. As a result of the limited number of patients with follow-up greater than 3 years, 3-and 5-year predictions may be less precise. Finally, we were unable to evaluate PC-specific mortality because cause of death was not available for all patients.
In conclusion, men with mCRPC have a poor prognosis, with most men dying within 13 months, which, adjusted to 2015, still amounted to a median survival of only 23 months. Age at mCRPC, more remote year of mCRPC diagnosis, greater number of bone metastasis, higher PSA levels, and shorter PSADT at mCRPC were significantly associated with shorter overall survival. Using these variables, we created a nomogram to predict the overall survival probability at 1, 2, 3, and 5 years. After external validation, the nomogram may help physicians and researches stratify mCRPC patients according to their risk of death.
Clinical Practice Points mCRPC patients generally have an unfavorable prognosis, but not all patients have an identical clinical course. While some patients quickly progress to widespread metastatic disease and die of cancer, others have a much more indolent disease progression. Previously, several predictive models have been proposed to estimate the survival of mCRPC patients. However, most of these studies used data from clinical trials evaluating patients after chemotherapy. We found that age, more remote year of mCRPC, greater number of bone metastasis, higher PSA levels, and shorter 
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PSADT at mCRPC diagnosis remained significantly associated with shorter overall survival. On the basis of these variables, a nomogram was generated yielding a concordance index of 0.67 and good calibration. After external validation, our nomogram may help physicians and researches stratify mCRPC patients according to their risk of death. 
Supplemental Data
Supplemental Figure 1 Distribution of Predicted Overall Survival at 2 Years After mCRPC Diagnosis
Abbreviation: mCRPC ¼ metastatic castration-resistant prostate cancer.
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